Vimseltinib
35 interactions 4 explained in plain English
Also sold as:
Romvimza
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
· Updated Jul 4, 2026
· Editorial policy
· Data sources
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Vimseltinib Relugolix Orgovyx Explained Increased risk of P-gp substrate exposure Details Vimseltinib Colchicine Colcrys Explained Increased risk of P-gp substrate exposure Details Vimseltinib Simvastatin Flolipid Explained Increased risk of BCRP substrate exposure Details Vimseltinib Aliskiren Tekturna Increased risk of P-gp substrate exposure Details Vimseltinib Alpelisib Piqray Increased risk of BCRP substrate exposure Details Vimseltinib Apixaban Eliquis Explained Increased risk of P-gp substrate exposure Details Vimseltinib Betrixaban Bevyxxa® Increased risk of P-gp substrate exposure Details Vimseltinib Afatinib Gilotrif Increased risk of P-gp substrate exposure Details Vimseltinib Cyclosporine Injection Atopica Increased risk of P-gp substrate exposure Details Vimseltinib Cyclosporine Ophthalmic Cequa Increased risk of P-gp substrate exposure Details Vimseltinib Dabigatran Pradaxa® Increased risk of P-gp substrate exposure Details Vimseltinib Dabigatran Etexilate Increased risk of P-gp substrate exposure Details Vimseltinib Dalfampridine Ampyra Increased risk of OCT2 substrate exposure Details Vimseltinib Darolutamide Nubeqa Increased risk of P-gp substrate exposure Details Vimseltinib Digoxin Cardoxin® Increased risk of P-gp substrate exposure Details Vimseltinib Dofetilide Tikosyn Increased risk of OCT2 substrate exposure Details Vimseltinib Doxorubicin Adriamycin Increased risk of P-gp substrate exposure Details Vimseltinib Edoxaban Savaysa Increased risk of P-gp substrate exposure Details Vimseltinib Everolimus Afinitor Increased risk of P-gp substrate exposure Details Vimseltinib Fexofenadine Allegra Increased risk of P-gp substrate exposure Details Vimseltinib Futibatinib Lytgobi Increased risk of P-gp substrate exposure Details Vimseltinib Gilteritinib Xospata Increased risk of P-gp substrate exposure Details Vimseltinib Irinotecan Camptosar Increased risk of BCRP substrate exposure Details Vimseltinib Irinotecan Injection Camptosar Increased risk of BCRP substrate exposure Details Vimseltinib Lefamulin Xenleta Increased risk of P-gp substrate exposure Details Vimseltinib Letermovir Injection Prevymis Increased risk of P-gp substrate exposure Details Vimseltinib Linagliptin Tradjenta Increased risk of P-gp substrate exposure Details Vimseltinib Loperamide Diamode Increased risk of P-gp substrate exposure Details Vimseltinib Maraviroc Selzentry Increased risk of P-gp substrate exposure Details Vimseltinib Metformin Fortamet® Increased risk of OCT2 substrate exposure Details Vimseltinib Methotrexate Jylamvo Increased risk of BCRP substrate exposure Details Vimseltinib Methotrexate Injection Abitrexate® Increased risk of BCRP substrate exposure Details Vimseltinib Naldemedine Symproic Increased risk of P-gp substrate exposure Details Vimseltinib Nintedanib Ofev Increased risk of P-gp substrate exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacistEducational information only, not medical advice. Always confirm interactions with your pharmacist
or prescriber before making any change to your medications.